Katharine Hazell

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Josep Tabernero, Federico Rojo, Emiliano Calvo et al. · Journal of Clinical Oncology · 2008 · 532 citations

Medicine, Oncology, Pharmacology +17

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Anne O’Donnell, Sandrine Faivre, Howard A. Burris et al. · Journal of Clinical Oncology · 2008 · 479 citations

Pharmacy, Oncology, Pharmacology +17

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

Chiaki Tanaka, Terence O’Reilly, John M. Kovarik et al. · Journal of Clinical Oncology · 2008 · 210 citations

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacokinetics, Metabolism, and Disposition of Deferasirox in β-Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State

Felix Waldmeier, Gerard Bruin, Ulrike Glaenzel et al. · Drug Metabolism and Disposition · 2010 · 89 citations

Medicine, Clinical Pharmacokinetics, Pharmacokinetics +16

A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors

Josep Tabernero, Federico Rojo, H.A. Burris et al. · Journal of Clinical Oncology · 2005 · 62 citations

Medicine, Oncology, Pharmacology +17